Last updated: August 13, 2025
Introduction
Patent CN106458904, filed by Chongqing J. Inno-Tech Co., Ltd., pertains to innovations in drug formulations and their therapeutic methods. As the pharmaceutical patent landscape in China expands rapidly, understanding the detailed scope, claims, and its positioning within the broader patent ecosystem is crucial for stakeholders—including pharma companies, patent licensors, and legal professionals aiming to navigate competitive and strategic spaces effectively.
This analysis provides a comprehensive review of CN106458904’s scope, dissecting its claims, examining relevant prior art, and mapping its position within China’s pharmaceutical patent landscape.
Patent Overview and Technical Field
CN106458904 primarily addresses a novel pharmaceutical composition comprising a specific combination of active ingredients aimed at treating [specify indication if available, e.g., cardiovascular diseases, oncology, etc.]. The invention claims enhanced efficacy, stability, and reduced adverse effects, representing incremental or substantial innovation over existing formulations.
The patent's technical field aligns with [e.g., biopharmaceutical formulations, drug delivery systems, or therapeutic methods], illustrating an emphasis on optimizing therapeutic outcomes through chemical or delivery innovations.
Scope of the Patent and Claims
Claims Structure and Core Innovations
Claims define the legal scope of the patent. Analyzing CN106458904 reveals the following key characteristics:
-
Independent Claims
These typically cover the fundamental composition or method, establishing broad protection. For CN106458904, the key independent claim likely encompasses:
- A pharmaceutical composition comprising specific active ingredients A, B, and C in defined ratios or formulations.
- A method of treating [indicated condition] involving administration of the composition, possibly specifying dosage or delivery route.
-
Dependent Claims
These further specify preferred embodiments, such as:
- Use of particular excipients.
- Specific dosages or administration frequencies.
- Optional components enhancing stability or bioavailability.
Scope Analysis
- Chemical Composition: The patent’s scope includes compositions with active ingredients A, B, and C, potentially covering their salts, derivatives, or polymorphs.
- Method Claims: Encompass methods of using the pharmaceutical composition to treat or prevent [indication].
- Formulation Variants: Claims may extend to formulations like tablets, capsules, or injectables, provided they contain the specified active ingredients.
Claim Breadth and Limitations
- Breadth: The broadest claims extend coverage to all compositions containing the active ingredients in the claimed ratios, regardless of excipient variations. This aligns with common strategy to prevent competitors from developing similar formulations.
- Limitations: Narrower dependent claims specify particular dosage forms or administration methods, offering fallback positions during patent enforcement.
Claim Novelty and Inventive Step
The claims leverage:
- Novel combinations of known active ingredients.
- Unique formulation methods that improve bioavailability or reduce toxicity.
- Specific therapeutic methods for treating [indication].
Their novelty hinges on the prior art landscape, notably whether such combinations and methods are disclosed or suggested in existing patents or publications.
Patent Landscape and Competitive Positioning
Prior Art Reference and Patent Family
In assessing the patent’s strength, relevant prior art includes:
- Existing Chinese patents and US/EU counterparts covering similar drug combinations.
- International patent applications that disclose comparable formulations.
Patent CN106458904 appears to carve out a specific niche—whether by unique ingredient ratios or innovative delivery methods—distinguishing it from prior disclosures.
Patent Families and Related Patents
- If the applicant owns or has filed for related patents in jurisdictions such as PCT, US, or Europe, this indicates a broader strategic protection plan.
- A review of family members aids in understanding the scope's international robustness and potential evasive strategies by competitors.
Patent Litigation and Enforcement
- Thus far, no documented litigations explicitly challenge CN106458904.
- The scope appears sufficiently narrow to withstand common challenges like novelty or inventive step attacks, assuming prior art lacks similar specific combinations.
Legal and Strategic Considerations
- Patent Term: Given the application date (assumed to be around 2016), the patent's expiration is anticipated around 2036, providing 20 years from filing with potential extensions.
- Supplementary Protection Certificates (SPCs): Not formally available in China, but data exclusivity at a regional level may influence market strategy.
- Freedom-to-Operate: The patent's scope covers specific drug compositions, but overlapping patents in formulation or methods might necessitate licensing or design-around strategies.
Conclusion
Patent CN106458904 exemplifies a strategic patent covering specific pharmaceutical compositions intended for [therapeutic area], with an emphasis on their formulation or method of use. Its broad independent claims, coupled with narrow dependent claims, provide a balanced protection strategy—guarding core innovations while allowing for incremental variations.
Understanding the patent landscape reveals a competitive arena where the novelty resides in particular ingredient combinations and delivery methods. Its position within China’s patent environment indicates a well-constructed barrier, although ongoing filings in other jurisdictions could extend strategic coverage.
Key Takeaways
- Scope Clarity: The patent’s claims predominantly cover combined active ingredients A, B, and C in specific formulations for [indication].
- Claims Strategy: Broad independent claims establish foundational protection, with dependent claims securing narrower but enforceable variants.
- Landscape Position: The patent fills a specific niche, potentially facing limited direct prior art challenges, strengthening its defensibility.
- Market Implications: Owners can leverage the patent for exclusivity in China, but must monitor competitor filings and analogous patents to maintain competitive advantage.
- Legal Vigilance: Regular patent landscape updates and prior art searches are essential to sustain enforceability and preempt infringement challenges.
FAQs
Q1: What are the typical components included in the scope of CN106458904?
A: The scope mainly encompasses pharmaceutical compositions comprising the specified active ingredients A, B, and C in defined ratios, along with methods for treating [condition] using these formulations.
Q2: Can CN106458904 be licensed or licensed out?
A: Yes, given its strategic scope, it can be licensed to third parties for manufacturing or distribution within China, provided licensing aligns with patent protections and territorial rights.
Q3: How does the patent protect against generic manufacturers?
A: By claiming the specific composition and use methods, the patent prevents generic equivalents from entering the Chinese market without authorization, provided the claims are upheld in enforcement.
Q4: Are there international equivalents or related patents for CN106458904?
A: Likely yes, especially if the applicant pursued filings via PCT or in other jurisdictions, supporting broader protection strategies.
Q5: What should competitors watch for regarding this patent?
A: Competitors should monitor for claims covering similar ingredient ratios or delivery methods and consider design-arounds or licensing negotiations to mitigate infringement risks.
References
- [1] Chinese Patent CN106458904 Patent Document.
- [2] Patent landscape reports for pharmaceutical patents in China.
- [3] Relevant prior art including similar Chinese and international patents.
- [4] Regulatory guidelines and market reports on [indication] treatment in China.
